Editor’s note: A livestream of this event will be embedded below at 1 p.m. ET.
Several biosimilar versions of Humira, which for years has been the world’s best-selling medicine, entered the U.S. market over the past year. What has that meant for insurance coverage and the way drugmakers are marketing these medicines? Join leading experts to discuss the impact on the industry and patients.
Straumann Holding AG / Key word(s): Annual Results/Dividend 27-Feb-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer
John Green, a novelist and high-profile YouTuber, is once again leveraging his star power in the global fight to end tuberculosis. His latest target? The
ATLANTA — An interatrial shunt failed to provide a clinical benefit to people with heart failure (HF) overall in the RELIEVE-HF trial, though actual harm